The phase 3 study (NCT07160634) of the SGT-003 gene therapy developed by Solid Biosciences is expected to begin in October 2025 and be completed in January 2029. The SGT-003 Phase 3 study will include 80 ambulant males, moreover the study locations have not yet been shared. Read More: Frequently Asked Questions About Solid Biosciences SGT-003 Gene Therapy
SGT-003 Gene Therapy Phase 3 Study – NCT07160634 –
This is a Phase 3, double-blind, placebo-controlled study with the primary objective of evaluating the efficacy of a single IV infusion of SGT-003 in pediatric ambulant male participants with DMD. The secondary objectives include the evaluation of additional efficacy and safety outcomes
Study Start (Estimated): 2025-10
Primary Completion (Estimated): 2029-01
Study Completion (Estimated): 2034-01
Number of Participants (Estimated): 80
Study Type: Interventional
Locations: No location data yet.
Ages Eligible for Study: 7 Years to 11 Years (Ambulant Males)
Principal inclusion and exclusion criteria. – NCT07160634 –
How to Participate in the SGT-003 Clinical Trial
To participate in the SGT-003 phase 3 clinical trial, you can use the contact information below.
Name: Solid Biosciences
Phone Number: 6173374680
Email: [email protected]
